

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**天津发展控股有限公司**  
**TIANJIN DEVELOPMENT HOLDINGS LIMITED**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 882)**

## **COMPLETION OF DISPOSAL OF TIANJIN SEGA PHARMACEUTICAL CO., LTD.**

References are made to the announcements of Tianjin Development Holdings Limited (the “**Company**”) dated 21 August 2017 and 1 December 2017 (the “**Announcements**”) in relation to the disposal of the entire equity interest of Segal Pharmaceutical held by Lisheng Pharmaceutical through public listing-for-sale process. Unless the context otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company was informed by Lisheng Pharmaceutical that the Disposal has been completed in accordance with the terms and conditions of the Equity Transfer Agreement. Upon Completion, Segal Pharmaceutical ceased to be a subsidiary of the Company and its financial results will no longer be consolidated into the financial statements of the Group.

By Order of the Board  
**Tianjin Development Holdings Limited**  
**Zeng Xiaoping**  
*Chairman*

Hong Kong, 28 December 2017

*As at the date of this announcement, the Board of the Company consists of Mr. Zeng Xiaoping, Mr. Wang Zhiyong, Dr. Cui Di, Dr. Yang Chuan, Mr. Cheung Wing Yui, Edward\*, Dr. Chan Ching Har, Eliza\*, Dr. Cheng Hon Kwan\*\*, Mr. Mak Kwai Wing, Alexander\*\*, Ms. Ng Yi Kum, Estella\*\*, Mr. Wong Shiu Hoi, Peter\*\* and Dr. Loke Yu\*\*.*

\* *non-executive director*

\*\* *independent non-executive director*